Back to top
more

Innoviva (INVA)

(Delayed Data from NSDQ)

$15.26 USD

15.26
415,799

+0.27 (1.80%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.27 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for INVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Innoviva, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 194 291 202 246 351
Receivables 84 64 111 94 79
Notes Receivable 0 0 0 0 0
Inventories 41 56 0 0 0
Other Current Assets 26 32 1 2 1
Total Current Assets 344 444 314 342 431
Net Property & Equipment 84 98 111 125 139
Investments & Advances 561 403 484 438 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 17 94 154
Intangibles 248 280 0 0 0
Deposits & Other Assets 3 4 0 0 0
Total Assets 1,244 1,232 926 1,000 725
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7 3 0 0 0
Current Portion Long-Term Debt 0 96 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 30 34 6 6 5
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 2 0 0 0
Total Current Liabilities 38 135 6 6 5
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1 6 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 446 444 395 386 377
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 84 81 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 569 666 400 392 383
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,093 1,164 1,264 1,261 1,259
Retained Earnings -25 -205 -456 -722 -946
Other Equity 0 0 111 68 29
Treasury Stock 394 394 394 0 0
Total Shareholder's Equity 675 566 526 608 342
Total Liabilities & Shareholder's Equity 1,244 1,232 926 1,000 725
Total Common Equity 675 566 526 608 342
Shares Outstanding 63.30 69.70 69.50 101.30 101.20
Book Value Per Share 10.66 8.12 7.57 6.00 3.38

Fiscal Year End for Innoviva, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 194 180 173 144
Receivables NA 84 68 81 76
Notes Receivable NA 0 0 0 0
Inventories NA 41 41 47 50
Other Current Assets NA 26 17 23 27
Total Current Assets NA 344 305 324 296
Net Property & Equipment NA 84 88 91 94
Investments & Advances NA 561 530 433 456
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 5 6 0
Intangibles NA 248 255 258 276
Deposits & Other Assets NA 3 3 4 4
Total Assets NA 1,244 1,188 1,118 1,130
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 7 4 5 6
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 30 31 31 30
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 1 2 3 2
Total Current Liabilities NA 38 36 39 38
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1 0 0 5
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 446 446 445 445
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 79 79 80
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 569 561 563 568
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 1,093 1,107 1,117 1,125
Retained Earnings NA -25 -87 -169 -170
Other Equity NA 0 0 0 0
Treasury Stock NA 394 394 394 394
Total Shareholder's Equity NA 675 627 555 561
Total Liabilities & Shareholder's Equity NA 1,244 1,188 1,118 1,130
Total Common Equity 0 675 627 555 561
Shares Outstanding 63.20 63.30 64.00 65.10 69.70
Book Value Per Share 0.00 10.66 9.80 8.53 8.06